Wells Fargo & Company Forecasts Strong Price Appreciation for Spyre Therapeutics (NASDAQ:SYRE) Stock

Spyre Therapeutics (NASDAQ:SYRE) had its price target raised by equities researchers at Wells Fargo & Company from $40.00 to $50.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would suggest a potential upside of 15.71% from the company’s previous close.

SYRE has been the topic of a number of other reports. JonesTrading upgraded Spyre Therapeutics from a “hold” rating to a “buy” rating and set a $64.00 price target on the stock in a research report on Monday, December 1st. Weiss Ratings restated a “sell (e+)” rating on shares of Spyre Therapeutics in a research note on Monday, December 29th. BTIG Research reiterated a “buy” rating and issued a $70.00 target price on shares of Spyre Therapeutics in a research note on Friday. Citigroup began coverage on shares of Spyre Therapeutics in a report on Wednesday, December 17th. They set a “buy” rating and a $64.00 price target for the company. Finally, Mizuho upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $53.44.

Spyre Therapeutics Stock Performance

NASDAQ SYRE opened at $43.21 on Friday. Spyre Therapeutics has a one year low of $10.91 and a one year high of $43.56. The company has a 50-day simple moving average of $33.40 and a 200-day simple moving average of $25.35. The firm has a market capitalization of $3.35 billion, a PE ratio of -20.77 and a beta of 3.15.

Spyre Therapeutics (NASDAQ:SYRE) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.04). Equities analysts forecast that Spyre Therapeutics will post -4.46 earnings per share for the current year.

Insider Transactions at Spyre Therapeutics

In other news, CEO Cameron Turtle sold 15,000 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $32.80, for a total value of $492,000.00. Following the completion of the transaction, the chief executive officer owned 657,540 shares of the company’s stock, valued at approximately $21,567,312. This represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In the last ninety days, insiders sold 45,000 shares of company stock worth $1,387,500. Insiders own 15.43% of the company’s stock.

Institutional Trading of Spyre Therapeutics

A number of institutional investors have recently made changes to their positions in SYRE. Optimize Financial Inc boosted its stake in shares of Spyre Therapeutics by 1.5% during the 4th quarter. Optimize Financial Inc now owns 25,331 shares of the company’s stock worth $830,000 after acquiring an additional 364 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Spyre Therapeutics by 0.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 106,664 shares of the company’s stock valued at $1,788,000 after purchasing an additional 522 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Spyre Therapeutics by 1.8% in the 2nd quarter. California State Teachers Retirement System now owns 33,201 shares of the company’s stock valued at $497,000 after purchasing an additional 603 shares during the period. F m Investments LLC increased its stake in Spyre Therapeutics by 1.4% in the 2nd quarter. F m Investments LLC now owns 52,546 shares of the company’s stock worth $787,000 after purchasing an additional 702 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in Spyre Therapeutics by 4.5% during the 4th quarter. AQR Capital Management LLC now owns 17,820 shares of the company’s stock worth $584,000 after buying an additional 773 shares during the period. 80.39% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Spyre Therapeutics

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and kept a $70 price target (roughly +62% upside vs. current levels), signaling strong buy-side conviction from a sell-side firm. BTIG Reaffirms Buy, $70 PT
• Positive Sentiment: Wells Fargo raised its price target to $50 and assigned an “overweight” rating, providing additional analyst support that likely helped lift the stock. Wells Fargo Raises PT to $50
• Positive Sentiment: Spyre reported a strong cash position — $757M in cash, equivalents and marketable securities as of 12/31/25 — and said that runway is expected into H2 2028, reducing near-term financing risk. The company also completed an offering in Oct 2025 and added a Chief Commercial Officer. Q4 & Corporate Update
• Positive Sentiment: Management reiterated an aggressive 2026 clinical cadence: up to six proof-of-concept readouts across the SKYLINE and SKYWAY Phase 2 programs (including Part A readouts starting in Q2 and multiple basket-study sub-readouts later in the year), which creates several near-term clinical catalysts. Clinical Readouts and Timeline
• Neutral Sentiment: Spyre announced presentations at the 21st ECCO Congress showcasing SPY003’s differentiated profile and preclinical combo data — supportive from a scientific/visibility standpoint but not an immediate financial catalyst. ECCO Presentations
• Negative Sentiment: Spyre missed the quarterly EPS consensus (reported -$0.70 vs. est. -$0.66), a modest miss that may temper sentiment for investors focused on near-term financials. Earnings Release

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.